Literature DB >> 3829011

Action of 7-ethylcamptothecin on tumor cells and its disposition in mice.

H Nagata, N Kaneda, T Furuta, S Sawada, T Yokokura, T Miyasaka, M Fukada, K Notake.   

Abstract

Some biological effects of camptothecin (CPT) and its new derivative 7-ethylcamptothecin (ECPT) were studied. The drugs were effective against murine leukemia; ECPT was more effective than CPT. Ip administration of ECPT or CPT gave maximum treated/control values of 325% and 232%, respectively. The drugs also inhibited the growth of KB cells in vitro, 50% effective doses of 3.5 ng/ml of ECPT and 8.6 ng/ml of CPT, indicating the stronger activity of ECPT. Pharmacokinetic studies of the drugs in mice showed that ECPT had a longer biological half-life in the terminal phase and a larger amount remained in the plasma compared with CPT. After iv administration of ECPT, the drug accumulated in the intestine, suggesting that the main route of excretion of the drug is through the biliary tract. The study on cell cycle progression by flow cytometry suggested that the main effect of both drugs on L1210 cells was the blocking of G2-M phase. These results suggest that the main reasons for the superior antitumor activity of ECPT compared with CPT are as follows: (a) ECPT had a stronger growth-inhibiting activity against tumor cells, and (b) ECPT remained in the intestinal tract for a longer time and in higher amounts when administered in vivo.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3829011

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  6 in total

1.  Structural Optimization and Enhanced Prodrug-Mediated Delivery Overcomes Camptothecin Resistance in High-Risk Solid Tumors.

Authors:  Ferro Nguyen; Peng Guan; David T Guerrero; Ivan S Alferiev; Michael Chorny; Garrett M Brodeur; Venkatadri Kolla; Koumudi Naraparaju; Lauren M Perry; Danielle Soberman; Benjamin B Pressly
Journal:  Cancer Res       Date:  2020-08-24       Impact factor: 12.701

2.  Inhibition of spontaneous and experimental metastasis by a new derivative of camptothecin, CPT-11, in mice.

Authors:  T Matsuzaki; T Yokokura; M Mutai; T Tsuruo
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Clinical studies of irinotecan alone and in combination with cisplatin.

Authors:  M Fukuoka; N Masuda
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

4.  Nanocarrier-Based Delivery of SN22 as a Tocopheryl Oxamate Prodrug Achieves Rapid Tumor Regression and Extends Survival in High-Risk Neuroblastoma Models.

Authors:  Ivan S Alferiev; David T Guerrero; Danielle Soberman; Peng Guan; Ferro Nguyen; Venkatadri Kolla; Ilia Fishbein; Blake B Pressly; Garrett M Brodeur; Michael Chorny
Journal:  Int J Mol Sci       Date:  2022-02-03       Impact factor: 5.923

5.  A pharmacokinetic and pharmacodynamic analysis of CPT-11 and its active metabolite SN-38.

Authors:  Y Sasaki; H Hakusui; S Mizuno; M Morita; T Miya; K Eguchi; T Shinkai; T Tamura; Y Ohe; N Saijo
Journal:  Jpn J Cancer Res       Date:  1995-01

6.  Construction of a Recombinant Porcine Epidemic Diarrhea Virus Encoding Nanoluciferase for High-Throughput Screening of Natural Antiviral Products.

Authors:  Wan Li; Mengjia Zhang; Huijun Zheng; Peng Zhou; Zheng Liu; Anan Jongkaewwattana; Rui Luo; Qigai He
Journal:  Viruses       Date:  2021-09-18       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.